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Should you bypass 
anticoagulant “bridging”  
before and after surgery? 
Skipping perioperative use of LMWH in low- and 
moderate-risk patients on warfarin for atrial fibrillation 
doesn’t increase their risk of stroke or bleeding.
PRACTICE CHANGER 
Stop using low molecular weight heparin 
(LMWH) for surgical procedures to “bridge” 
low- to moderate-risk patients with atrial fi-
brillation (CHADS2 score ≤4) who are receiv-
ing warfarin. The risks outweigh the benefits.1
STRENGTH OF RECOMMENDATION
B: Based on a single good-quality random-
ized control trial.
Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridg-
ing anticoagulation in patients with atrial fibrillation. N Engl J Med. 
2015;373:823-833. 
ILLUSTRATIVE CASE
A 75-year-old man comes to your office for 
surgical clearance before right knee replace-
ment surgery. He has diabetes and high blood 
pressure, and is taking warfarin for atrial fi-
brillation. He is scheduled for surgery in a 
week. What is the safest way to manage his 
warfarin in the perioperative period?
More than 2 million people are be-ing treated with oral anticoagula-tion in North America to prevent 
stroke, or to prevent or treat venous throm-
boembolism.2 Since 2010, several new oral 
anticoagulants have been approved, includ-
ing dabigatran, apixaban, and rivaroxaban. 
These new medications have a shorter half-
life than older anticoagulants, which enables 
them to be stopped 1 to 2 days before surgery. 
On the other hand, warfarin—which 
remains a common choice for anticoagula-
tion—has a 3- to 7-day onset and elimina-
tion.3,4   This long clinical half-life presents a 
special challenge during the perioperative 
period. To reduce the risk of operative bleed-
ing, the warfarin must be stopped days prior 
to the procedure, but physicians often worry 
that this will increase the risk of arterial or ve-
nous thromboembolism, including stroke. 
An estimated 250,000 patients need 
perioperative management of their anticoag-
ulation each year.5 As the US population con-
tinues to age and the incidence of conditions 
requiring anticoagulation (particularly atrial 
fibrillation) increases, this number is only go-
ing to rise.6 
❚ Current guidelines on bridging. 
American College of Chest Physicians 
(ACCP) guidelines recommend transition to 
“a short-acting anticoagulant, consisting of 
subcutaneous low molecular weight hepa-
rin (LMWH) or intravenous unfractionated 
heparin, for a 10- to 12-day period during 
interruption of vitamin K antagonist  (VKA) 
therapy.”5 Furthermore, for an appropriate 
bridging regimen, the ACCP guidelines rec-
ommend stopping VKA therapy 5 days prior 
to the procedure and utilizing LMWH from 
within 24 to 48 hours of stopping VKA therapy 
until up to 24 hours before surgery.5 Postop-
eratively, VKA or LMWH therapy should be 
reinitiated within 24 hours and 24 to 72 hours, 
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respectively, depending on the patient’s risk 
of bleeding during surgery.5 
These guidelines recommend using 
CHADS2 scoring (TABLE3) to determine arte-
rial thromboembolism (ATE) risk in atrial 
fibrillation.3,5 Patients at low risk for ATE 
(CHADS2 score 0-2) should not be bridged, 
and patients at high risk (CHADS2 score of 
5-6) should always be bridged.5 These guide-
lines are less clear about bridging recommen-
dations for moderate-risk patients (CHADS2 
score 3-4). 
❚ Previous evidence on bridging. A 2012 
meta-analysis of 34 studies evaluated the 
safety and efficacy of perioperative bridging 
with heparin in patients receiving VKA.7 Re-
searchers found no difference in ATE events in 
8 studies that compared groups that received 
bridging vs groups that simply stopped anti-
coagulation (odds ratio [OR]=0.80; 95% con-
fidence interval [CI], 0.42–1.54).7 The group 
that received bridging had an increased risk 
of overall bleeding in 13 studies, and of major 
bleeding in 5 studies.7 This meta-analysis was 
limited by poor study quality and variation in 
the indication for VKA therapy. 
A 2015 subgroup analysis of a larger 
cohort study of patients receiving anti-
coagulants for atrial fibrillation found an 
increased risk of bleeding when their anti-
coagulation was interrupted for procedures 
(OR for major bleeding=3.84; 95% CI, 2.07-
7.14; P<.0001).8
Douketis et al1 conducted a random-
ized trial to clarify the need for and safety of 
bridging anticoagulation for ATE in patients 
with atrial fibrillation who were receiving 
warfarin.
STUDY SUMMARY
When it comes to stroke/TIA,  
there’s no advantage to bridging 
This double blind, placebo-controlled trial 
compared bridging with dalteparin, a form 
of LMWH, to placebo among 1884 patients 
with atrial fibrillation on warfarin whose 
anticoagulation therapy needed to be inter-
rupted for an elective procedure. Patients 
were included if they were receiving warfarin 
to prevent stroke, and had been on warfarin 
for at least 12 weeks, with a goal international 
normalized ratio (INR) of 2.0 to 3.0. Exclusion 
criteria included having a mechanical heart 
valve or having a stroke/transient ischemic 
attack (TIA; 12 weeks prior) or major bleed-
ing (6 weeks prior). Cardiac, intracranial, and 
intraspinal surgeries were also excluded from 
the study.
The patients’ mean CHADS2 score was 
2.3; 38.3% of patients had a CHADS2 score ≥3, 
and 9.4% of patients had a history of stroke. 
Forty-four percent of patients underwent a 
gastrointestinal procedure, 17.2% underwent 
a cardiothoracic procedure, and 9.2% under-
went an orthopedic procedure. 
Patients stopped taking warfarin 5 days be-
fore their procedure, and began subcutaneous 
dalteparin, 100 IU/kg, or an identical placebo 
3 days before the procedure. The dalteparin/
placebo was stopped 24 hours before the pro-
cedure and restarted after the procedure, until 
the patient’s INR was in the therapeutic range. 
Warfarin was resumed on the evening of the 
procedure or the following day. 
The primary efficacy outcome was ATE, 
including stroke, TIA, or systemic embolism. 
The primary safety endpoint was major bleed-
ing (defined as bleeding at a critical anatomic 
site, symptomatic or clinically overt bleeding, 
or a decrease in hemoglobin >2 g/dL). Sec-
ondary efficacy and safety outcomes included 
minor bleeding, acute myocardial infarction, 
deep vein thrombosis, pulmonary embolism, 
and death. Outcomes were assessed within 
37 days of the procedure.
The incidence of ATE was 0.4% (4 events) 
Guidelines are 
not clear about 
whether  
patients at  
moderate risk  
of arterial 
thrombo embolism 
need bridging. 
TABLE 
CHADS2: Assessment of  
arterial thromboembolic risk 
in atrial fibrillation3
Risk factor (CHADS2) Score
Congestive heart failure 1
Hypertension 1
Age >75 years 1
Diabetes mellitus 1
Stroke/TIA 2
Maximum score 6
TIA, transient ischemic attack.
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This study  
suggests 
patients who 
receive bridging 
have a higher 
risk of bleeding 
than stroke.
in the no-bridging group vs 0.3% (3 events) 
in the bridging group (95% CI, -0.6 to 0.8; 
P=.01 for non-inferiority; P=.73 for superior-
ity). Major bleeding occurred in 1.3% of the 
no-bridging group (12 events) and in 3.2% 
of the bridging group (29 events), indicating 
that no bridging was superior in terms of the 
major bleeding outcome (number needed to 
harm [NNH]=53; relative risk [RR]=0.41; 95% 
CI, 0.20-0.78; P=.005). The no-bridging group 
also had significantly fewer minor bleeds in 
comparison to the bridging group (NNH=11; 
12% vs 20.9%; P<.001). There were no differ-
ences between groups in other secondary 
outcomes. 
WHAT’S NEW
High-quality evidence suggests it’s OK 
to stop warfarin before surgery 
This is the largest good-quality study to eval-
uate perioperative bridging in patients with 
atrial fibrillation who were at low or moder-
ate risk for ATE (CHADS2 score 0-4). Previous 
studies suggested bridging increased bleed-
ing and offered limited benefit for reducing 
the risk of ATE. However, this is the first study 
to include a large group of moderate-risk pa-
tients (CHADS2 score 3-4). This trial provides 
high-quality evidence to support the practice 
of simply stopping warfarin in the periopera-
tive period, rather than bridging with LMWH.
CAVEATS
Findings might not apply  
to patients at highest risk
Most patients in this study had a CHADS2 
score ≤3. About 3% had a CHADS2 score ≥5 or 
higher. It’s not clear whether these findings ap-
ply to patients with a CHADS2 score of 5 or 6.
This trial categorized ATE risk using the 
CHADS2 score, rather than the CHA2DS2-
VASc, which includes additional risk fac-
tors and may more accurately predict stroke 
risk. Both patients who received bridging 
therapy and those who did not had a lower 
rate of stroke than predicted by CHADs2. 
This may reflect a limit of the predictive val-
ue of CHADS2, but should not have affected 
the rate of bleeding or ATE outcomes in this 
study.
CHALLENGES TO IMPLEMENTATION
Physicians may hesitate  
to disregard current guidelines 
Strokes are devastating events for patients, 
families, and physicians, and they pose a 
greater risk of morbidity and mortality com-
pared to bleeding. However, this study sug-
gests patients who receive bridging have a 
higher risk of bleeding than stroke, which is 
in contrast to some physicians’ experience 
and current recommendations. 
A physician caring for a patient who’s 
had a stroke may be inclined to recommend 
bridging despite the lack of efficacy and evi-
dence of bleeding risk. Additionally, until 
guidelines reflect the most current research, 
physicians may be reluctant to provide care 
in contrast to these recommendations.         JFP
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